Estados Unidos · Plataformas y datos · Finviz

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Publicado por Finviz · Estados Unidos hace 11 h

Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO ® upon close and infliximab-abda in Q3 2027; Collaboration combines Samsung Bioepis’ biosim ...

Leer el artículo completo en Finviz Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finviz.com)

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

También te puede interesar

Why Did Bloom Energy Stock Jump 10% Today?

Want to help your adult kids and grandkids? Give them money while you’re still alive.

Energy Vault (NRGV) Set to Post Quarterly Earnings on Tuesday

Colorado homeowners face $7,000 to $20,700 HOA special assessments for hail-damaged roofs — or risk foreclosure

Morgan Stanley's Ariana Salvatore on U.S. midterms: Executive policy is the story for markets

Analyst sends big warning on gold and bitcoin amid U.S. midterms

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Compartir

También te puede interesar

Why Did Bloom Energy Stock Jump 10% Today?

Want to help your adult kids and grandkids? Give them money while you’re still alive.

Energy Vault (NRGV) Set to Post Quarterly Earnings on Tuesday

Colorado homeowners face $7,000 to $20,700 HOA special assessments for hail-damaged roofs — or risk foreclosure

Morgan Stanley's Ariana Salvatore on U.S. midterms: Executive policy is the story for markets

Analyst sends big warning on gold and bitcoin amid U.S. midterms